Pacira Seeks Board Support, Touts EXPAREL's Opioid & Cost Reduction Data
PCRX sits 28% above its 52-week low of $18.8.
Summary
Pacira BioSciences is actively campaigning for shareholder votes to support its board nominees in the ongoing proxy contest. Concurrently, the company released new Optum data (2019-2024) showing its flagship product, EXPAREL, significantly reduces opioid use and healthcare costs in outpatient shoulder arthroplasty. This proxy push follows months of SEC filings detailing the battle with activist investor DOMA Perpetual Capital Management. The positive EXPAREL data is critical for reinforcing the product's market position and for the company's defense of its current board and strategy.
At the time of this announcement, PCRX was trading at $24.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $945.6M. The 52-week trading range was $18.80 to $27.64. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.